Support for growth through the partial transfer of shares in JR Kyushu Drug Eleven to Tsuruha
First written in FY2021-Q1. 2 of 3 entries say "Achieved", first in FY2023. Latest entry: FY2024-Q1.
No other company in this theme has enough history to compare yet.
- FY2024-Q1AchievedAnnual report
「Drug Eleven Co., Ltd., previously an equity-method affiliate, was removed from the scope of equity-method application from the end of the first quarter of the consolidated fiscal year because all of the shares held were transferred.」
The transfer of all shares in Drug Eleven was completed, finalizing the restructuring of the ownership relationship to support the company’s growth. - FY2023AchievedAnnual report
「After extensive consideration under these circumstances, we determined that the optimal way to achieve further business growth and enhance the corporate value of the target company was for it to operate as a wholly owned subsidiary of Tsuruha Holdings, and decided to proceed with the transfer of the shares to the Tsuruha Group.」
For JR Kyushu Drug Eleven, the decision to transfer all shares to the Tsuruha Group was made, completing the policy of supporting growth through making it a wholly owned subsidiary. - FY2021-Q1First statedAnnual report
「We determined that, to achieve further business growth and enhance the corporate value of the target company, the best course was to transfer a portion of its shares to Tsuruha, enabling the target company to leverage its strengths and characteristics as well as the management resources and business expertise of the Tsuruha Group, with the aim of achieving further growth as a company combining regional focus and profitability.」
A portion of the shares in JR Kyushu Drug Eleven was transferred to Tsuruha Holdings to support its growth and enhance its corporate value.